Aposense has signed a collaboration agreement with Roche to use Aposense’s EarliTest for imaging apoptosis (programmed cell death) in oncology clinical trials.

EarliTest comprises the ML-10 imaging agent for imaging apoptosis with PET and dedicated image analysis software. Under the terms of the non-exclusive agreement, Roche will fund the clinical trials and pay Aposense certain license and milestone fees, in undisclosed amounts.

Aposense, based in Petach-Tikva, Israel added that EarliTest is designed to image tumor response early during treatment and has the potential to accelerate drug development by providing feedback on the biological effect of treatment very early on.